Novel, rare and common pathogenic variants in the CFTR gene screened by high-throughput sequencing technology and predicted by in silico tools

被引:40
作者
Pereira, Stephanie Villa-Nova [1 ]
Ribeiro, Jose Dirceu [2 ,3 ]
Ribeiro, Antonio Fernando [2 ]
Bertuzzo, Carmen Silvia [1 ]
Lima Marson, Fernando Augusto [1 ,2 ,3 ]
机构
[1] Univ Estadual Campinas, Sch Med Sci, Dept Med Genet & Genom Med, Tessalia Vieira Camargo 126, BR-13083887 Campinas, SP, Brazil
[2] Univ Estadual Campinas, Sch Med Sci, Dept Pediat, Tessalia Vieira Camargo 126, BR-13083887 Campinas, SP, Brazil
[3] Univ Estadual Campinas, Sch Med Sci, Ctr Pediat Invest, Lab Pulm Physiol, Tessalia Vieira Camargo 126, BR-13083887 Campinas, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
CYSTIC-FIBROSIS; DISEASE; GUIDELINES; GENOMICS; IDENTIFICATION; DIAGNOSIS; CONSENSUS; GENOTYPE;
D O I
10.1038/s41598-019-42404-6
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Cystic fibrosis (CF) is caused by similar to 300 pathogenic CFTR variants. The heterogeneity of which, challenges molecular diagnosis and precision medicine approaches in CF. Our objective was to identify CFTR variants through high-throughput sequencing (HTS) and to predict the pathogenicity of novel variants through in 8 silico tools. Two guidelines were followed to deduce the pathogenicity. A total of 169 CF patients had genomic DNA submitted to a Targeted Gene Sequencing and we identified 63 variants (three patients had three variants). The most frequent alleles were: F508del (n = 192), G542* (n = 26), N1303K (n = 11), R1162* and R334W (n = 9). The screened variants were classified as follows: 41 - pathogenic variants [classified as (I) n = 23, (II) n = 6, (III) n = 1, (IV) n = 6, (IV/V) n = 1 and (VI) n = 4]; 14 - variants of uncertain significance; and seven novel variants. To the novel variants we suggested the classification of 6b-16 exon duplication, G646* and 3557delA as Class I. There was concordance among the predictors as likely pathogenic for L935Q, cDNA. 5808T>A and I1427I. Also, Y325F presented two discordant results among the predictors. HTS and in silico analysis can identify pathogenic CFTR variants and will open the door to integration of precision medicine into routine clinical practice in the near future.
引用
收藏
页数:16
相关论文
共 50 条
[1]   A method and server for predicting damaging missense mutations [J].
Adzhubei, Ivan A. ;
Schmidt, Steffen ;
Peshkin, Leonid ;
Ramensky, Vasily E. ;
Gerasimova, Anna ;
Bork, Peer ;
Kondrashov, Alexey S. ;
Sunyaev, Shamil R. .
NATURE METHODS, 2010, 7 (04) :248-249
[2]  
Athanazio RA, 2017, J BRAS PNEUMOL, V43, P219, DOI [10.1590/s1806-37562017000000065, 10.1590/S1806-37562017000000065]
[3]   PURIFICATION AND FUNCTIONAL RECONSTITUTION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) [J].
BEAR, CE ;
LI, CH ;
KARTNER, N ;
BRIDGES, RJ ;
JENSEN, TJ ;
RAMJEESINGH, M ;
RIORDAN, JR .
CELL, 1992, 68 (04) :809-818
[4]   Current and future molecular approaches in the diagnosis of cystic fibrosis [J].
Bergougnoux, Anne ;
Taulan-Cadars, Magali ;
Claustres, Mireille ;
Raynal, Caroline .
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2018, 12 (05) :415-426
[5]   A false positive newborn screening result due to a complex allele carrying two frequent CF-causing variants [J].
Bergougnoux, Anne ;
Boureau-Wirth, Amandine ;
Rouzier, Cecile ;
Altieri, Jean-Pierre ;
Verneau, Fanny ;
Larrieu, Lise ;
Koenig, Michel ;
Claustres, Mireille ;
Raynal, Caroline .
JOURNAL OF CYSTIC FIBROSIS, 2016, 15 (03) :309-312
[6]   CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease [J].
Bonadia, Luciana Cardoso ;
de Lima Marson, Fernando Augusto ;
Ribeiro, Jose Dirceu ;
Paschoal, Ilma Aparecida ;
Pereira, Monica Corso ;
Ribeiro, Antonio Fernando ;
Bertuzzo, Carmen Silvia .
GENE, 2014, 540 (02) :183-190
[7]   Cystic fibrosis: a disease of vulnerability to airway surface dehydration [J].
Boucher, Richard C. .
TRENDS IN MOLECULAR MEDICINE, 2007, 13 (06) :231-240
[8]   Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice [J].
Castellani, C. ;
Cuppens, H. ;
Macek, M., Jr. ;
Cassinian, J. J. ;
Kerern, E. ;
Durie, P. ;
Tullis, E. ;
Assael, B. M. ;
Bombieri, C. ;
Brown, A. ;
Casals, T. ;
Claustres, M. ;
Cutting, G. R. ;
Dequeker, E. ;
Dodge, J. ;
Doull, I. ;
Farrell, P. ;
Ferec, C. ;
Girodon, E. ;
Johannesson, M. ;
Kerem, B. ;
Knowles, M. ;
Munck, A. ;
Pignatti, P. F. ;
Radojkovic, D. ;
Rizzotti, P. ;
Schwarz, M. ;
Stuhnnann, M. ;
Tzetis, M. ;
Zielenski, J. ;
Elborn, J. S. .
JOURNAL OF CYSTIC FIBROSIS, 2008, 7 (03) :179-196
[9]   ECFS best practice guidelines: the 2018 revision [J].
Castellani, Carlo ;
Duff, Alistair J. A. ;
Bell, Scott C. ;
Heijerman, Harry G. M. ;
Munck, Anne ;
Ratjen, Felix ;
Sermet-Gaudelus, Isabelle ;
Southern, Kevin W. ;
Barben, Jurg ;
Flume, Patrick A. ;
Hodkova, Pavia ;
Kashirskaya, Nataliya ;
Kirszenbaum, Maya N. ;
Madge, Sue ;
Oxley, Helen ;
Plant, Barry ;
Schwarzenberg, Sarah Jane ;
Smyth, Alan R. ;
Taccetti, Giovanni ;
Wagner, Thomas O. F. ;
Wolfe, Susan P. ;
Drevinek, Pavel .
JOURNAL OF CYSTIC FIBROSIS, 2018, 17 (02) :153-178
[10]   Cystic fibrosis: a clinical view [J].
Castellani, Carlo ;
Assael, Baroukh M. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2017, 74 (01) :129-140